IART Overzicht aandelen
Integra LifeSciences Holdings Corporation produceert en verkoopt chirurgische instrumenten, neurochirurgische producten en wondverzorgingsproducten voor gebruik in de neurochirurgie, neurokritische zorg en otolaryngologie. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 5/6 |
| Toekomstige groei | 3/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 2/6 |
| Dividenden | 0/6 |
Integra LifeSciences Holdings Corporation Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$23.58 |
| 52 Week Hoogtepunt | US$45.42 |
| 52 Week Laag | US$16.81 |
| Bèta | 1.08 |
| 11 maand verandering | 24.43% |
| 3 maanden verandering | 14.91% |
| 1 Jaar Verandering | -39.04% |
| 33 jaar verandering | -63.62% |
| 5 jaar verandering | -61.22% |
| Verandering sinds IPO | 409.84% |
Recent nieuws en updates
There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise
Nov 05
Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Oct 24Recent updates
There's No Escaping Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Muted Revenues Despite A 42% Share Price Rise
Nov 05Is Now The Time To Look At Buying Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Oct 24Why Investors Shouldn't Be Surprised By Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Low P/S
Sep 08Is Integra LifeSciences Holdings (NASDAQ:IART) A Risky Investment?
Aug 21At US$29.14, Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Worth Looking At Closely?
Jul 01Integra LifeSciences Still Underperforming As Manufacturing Issues Linger
Jun 21Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Intrinsic Value Is Potentially 40% Above Its Share Price
May 28Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Stalled
Feb 27We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Feb 11Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Jan 14Integra LifeSciences Holdings Corporation's (NASDAQ:IART) Price In Tune With Earnings
Dec 31Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 46% Discount?
Dec 03Does Integra LifeSciences Holdings (NASDAQ:IART) Have A Healthy Balance Sheet?
Nov 06Integra LifeSciences Holdings (NASDAQ:IART) Hasn't Managed To Accelerate Its Returns
Oct 24Is Now An Opportune Moment To Examine Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Sep 22Is Integra LifeSciences Holdings Corporation (NASDAQ:IART) Trading At A 38% Discount?
Aug 15Returns On Capital At Integra LifeSciences Holdings (NASDAQ:IART) Have Hit The Brakes
Jul 03Is There Now An Opportunity In Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Jun 19Estimating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
May 05These 4 Measures Indicate That Integra LifeSciences Holdings (NASDAQ:IART) Is Using Debt Reasonably Well
Apr 07Integra LifeSciences Holdings (NASDAQ:IART) Is Experiencing Growth In Returns On Capital
Mar 26At US$52.61, Is It Time To Put Integra LifeSciences Holdings Corporation (NASDAQ:IART) On Your Watch List?
Mar 14Does Integra LifeSciences Holdings (NASDAQ:IART) Deserve A Spot On Your Watchlist?
Feb 27Calculating The Fair Value Of Integra LifeSciences Holdings Corporation (NASDAQ:IART)
Feb 02We Think Integra LifeSciences Holdings (NASDAQ:IART) Can Stay On Top Of Its Debt
Jan 05Here's What To Make Of Integra LifeSciences Holdings' (NASDAQ:IART) Decelerating Rates Of Return
Dec 21When Should You Buy Integra LifeSciences Holdings Corporation (NASDAQ:IART)?
Dec 08Rendement voor aandeelhouders
| IART | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 4.8% | 1.5% | 2.2% |
| 1Y | -39.0% | 20.8% | 31.6% |
Rendement versus industrie: IART presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van 20.8 % opleverde.
Rendement versus markt: IART presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 31.6 % opleverde.
Prijsvolatiliteit
| IART volatility | |
|---|---|
| IART Average Weekly Movement | 9.0% |
| Medical Equipment Industry Average Movement | 8.1% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: IART heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van IART is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1989 | 3,946 | Jan De Witte | www.integralife.com |
Integra LifeSciences Holdings Corporation produceert en verkoopt chirurgische instrumenten, neurochirurgische producten en wondverzorgingsproducten voor gebruik in de neurochirurgie, neurokritische zorg en otolaryngologie. Het bedrijf is actief in twee segmenten, Codman Specialty Surgical en Tissue Technologies. Het bedrijf biedt neurochirurgische en neurokritische zorgproducten aan, waaronder weefselablatieapparatuur, producten voor duraal herstel, apparatuur voor het beheer van cerebraal ruggenmergvocht, intracraniële bewakingsapparatuur en apparatuur voor schedelstabilisatie; en chirurgische hoofdlampen en instrumenten, evenals aftermarket-diensten.
Integra LifeSciences Holdings Corporation Samenvatting
| IART fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$1.82b |
| Inkomsten(TTM) | -US$6.54m |
| Inkomsten(TTM) | US$1.56b |
1.2x
P/S-verhouding-278.0x
Koers/WinstverhoudingIs IART overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| IART resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$1.56b |
| Kosten van inkomsten | US$632.40m |
| Brutowinst | US$932.52m |
| Overige uitgaven | US$939.06m |
| Inkomsten | -US$6.54m |
Laatst gerapporteerde inkomsten
Sep 30, 2024
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.085 |
| Brutomarge | 59.59% |
| Nettowinstmarge | -0.42% |
| Schuld/Eigen Vermogen Verhouding | 118.9% |
Hoe presteerde IART op de lange termijn?
Bekijk historische prestaties en vergelijking